- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03439215
PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer (PFROST)
PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer: a Phase II Trial (PFROST)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PF-06463922 is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration. The results showed that PF-06463922 is most potent against ROS1 and ALK, with selectivity ratios >100-fold for ROS1 over the 204 kinases tested. A recent study has investigated the activity of PF-06463922 against the crizotinib-resistant ROS1G2032R mutation in both recombinant enzyme and cell-based assays. PF-06463922 effectively inhibited the catalytic activity of recombinant ROS1G2032R and the CD74-ROS1G2032R fusion kinase in BaF3 cells. This effect translated directly into an antiproliferative response. These results, together with its exquisite ROS1 potency and ability to suppress the resistant ROS1 mutations, supports the clinical evaluation of PF-06463922 in ROS1-positive NSCLC, including patients who have developed resistance to crizotinib because of the acquired G2032R mutation and/or brain metastases.
This is a phase II study assessing response rate to PF-06463922 in patients with ROS1 translocation resistant to previous crizotinib therapy. Eligible patients will be treated with the study drug until disease progression, unacceptable toxicity or patient refusal. Disease assessment will be performed every 8 weeks according to RECIST criteria.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Arezzo, Italy, 52100
- Istituto Toscano Tumori Ospedale San Donato- U.O.C. di Oncologia Medica Dipartimento di Oncologia USL-8
-
Avellino, Italy, 83100
- Azienda Ospedaliera di Rilievo Nazionale "S.G. Moscati"
-
Bari, Italy, 70124
- Irccs Istituto Tumori Giovanni Paolo Ii
-
Genova, Italy, 16132
- IRCCS A.O.U. San Martino- IST- Istituto Nazionale per la Ricerca sul Cancro- U.O.S. Tumori Polmonari
-
Milano, Italy, 20141
- Istituto Europeo di Oncologia - Divisione di Oncologia Toracica
-
Modena, Italy, 41124
- A.O.U. Policlinico di Modena- Oncologia Ematologia e Malattie Apparato Respiratorio
-
Monza, Italy, 20900
- A.O. San Gerardo
-
Napoli, Italy, 80131
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
-
Padova, Italy, 35128
- Istituto Oncologico Veneto IRCCS- UOS Oncologia Toracica UOC. Oncologia Medica 2
-
Palermo, Italy, 90146
- Casa di Cura La Maddalena- U.O. Oncologia medica
-
Parma, Italy, 43126
- Azienda Ospedaliera Universitaria di Parma- Struttura Complessa di Oncologia Medica
-
Perugia, Italy, 06132
- Azienda Ospedaliera di Perugia- S.C. Oncologia Medica
-
Ravenna, Italy, 48121
- Ospedale di Ravenna- Oncologia Medica
-
Rimini, Italy, 47900
- Ospedale "Infermi" Rimini
-
Saronno, Italy, 21047
- ASST della Valle Olona - Ospedale di Saronno
-
Torino, Italy, 10043
- A.O.U. San Luigi Gonzaga
-
Treviso, Italy, 31100
- Azienda ULSS 9 TREVISO-UOC Oncologia Medica
-
Verona, Italy, 37134
- Policlinico 'G.B.Rossi' Borgo Roma - A.O.U. Integrata (Giampaolo Tortora)- Oncologia Medica
-
-
Forlì- Cesena
-
Meldola, Forlì- Cesena, Italy, 47014
- IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)- Oncologia Medica
-
-
Verona
-
Negrar, Verona, Italy, 37024
- Sacro Cuore- Don Calabria Hospital- U.O.C. Oncologia Medica
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent;
- Male or female patient ages ≥ 18 years;
- Histologically/cytologically confirmed diagnosis of NSCLC with evidence of ROS1 rearrangement;
- Possibility to perform a new tumor biopsy or tumor tissue collected at the time or after crizotinib failure;
- Patient pretreated with crizotinib with evidence of disease progression during crizotinib therapy;
- At least one radiological measurable disease according to RECIST criteria;
- At least 1 previous standard chemotherapy regimen;
- Performance status 0-2 (ECOG);
- Patient compliance to trial procedures
- Adequate bone marrow function (ANC ≥ 1.5x109/L, platelets ≥ 100x109/L, haemoglobin > 9 g/dl);
- Adequate liver function (bilirubin < grade 2, transaminases no more than 3xULN/<5xULN in present of liver metastases);
- Normal level of alkaline phosphatase and creatinine;
- If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of approved contraceptive method [intrauterine contraceptive device (IUD), birth control pills, or barrier device] during and for ninety (90) days after end of treatment.
Exclusion Criteria:
1. No ROS1 rearrangement 2. No previous therapy with crizotinib; 3. No evidence of crizotinib failure; 4. No post-crizotinib tumor tissue available; 5. Absence of any measurable lesions; 6. No previous chemotherapy; 7. Concomitant radiotherapy or chemotherapy; 8. Symptomatic brain metastases; 9. Diagnosis of any other malignancy during the last 5 years, except for in situ carcinoma of cervix uteri and squamous cell carcinoma of the skin; 10. Predisposing factors for acute pancreatitis (e.g., uncontrolled hyperglycaemia, current gallstone disease, alcoholism); 11. History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis (but not history of prior radiation pneumonitis); 12. Pregnancy or lactating female; 13. Other serious illness or medical condition potentially interfering with the study.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lorlatinb Arm
Eligible patients will be treated with Lorlatinib at the dose of 100 mg QD p.o.
|
Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate to PF-06463922 in patients with ROS1 translocation resistant to crizotinib
Time Frame: From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
|
Response rate to PF-06463922 in patients with ROS1 translocation resistant to crizotinib
|
From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS), The length of time during and after the treatment of a disease,that a patient lives with the disease but it doesn't get worse.
Time Frame: From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
|
Progression-free survival (PFS) will be calculated from the time between the baseline/start of treatment visit to the time of first occurrence of progressive disease (PD) or death from any cause.
Patients who have neither progressed nor died at time of analysis will be censored at the date of last tumor assessment where non progression was documented (i.e.
CR, PR or SD)
|
From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
|
Overall Survival (OS): Time from the start of treatment until death from any cause
Time Frame: From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
|
Overall survival (OS) will be calculated from the time between the baseline/start of treatment visit to the date of death, irrespective of the cause of death.
Patients still alive at the time of analysis will be censored at the date they were last known to be alive
|
From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
|
Patients will be closely monitored for signs and symptoms of potential adverse events, and will undergo frequent laboratory tests to assess lipids, pancreas, liver, kidney, and haematological function.
|
From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
|
Correlation with additional tumor biomarkers in tumor tissue or blood
Time Frame: From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
|
Correlation with additional tumor biomarkers in tumor tissue or blood
|
From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FoRT 01/2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Lorlatinib
-
Guangdong Provincial People's HospitalRecruiting
-
PfizerTerminated
-
Massachusetts General HospitalRecruitingNon-Small Cell Lung Cancer (NSCLC)United States
-
Intergroupe Francophone de Cancerologie ThoraciqueActive, not recruitingNon Small Cell Lung Cancer MetastaticFrance
-
PfizerTerminatedNeuroblastomaAustralia, Korea, Republic of, United States, Portugal, New Zealand, Sweden
-
Nationwide Children's HospitalPfizerNot yet recruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | WHO Grade III Glioma | WHO Grade IV Glioma | Infant Type Hemispheric Glioma | Diffuse Midline Glioma, H3K27-alteredUnited States, Australia, Canada, Germany, Netherlands
-
PfizerCompletedAdvanced Non-Small Cell Lung CancerIndia
-
Guangdong Association of Clinical TrialsNot yet recruitingCarcinoma, Non-Small-Cell Lung | Brain Metastases | Leptomeningeal MetastasisChina
-
Sichuan Cancer Hospital and Research InstituteRecruitingALK-positive Non-small Cell Lung Cancer | Real World StudyChina